Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.

Biomed Pharmacother · 2022 · PMC8767802 · PMID 35066301

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Heterologous vaccine administration showed a trend toward more frequent systemic reactions.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.